First phase 3 study evaluating Cimzia® (certolizumab pegol) in early rheumatoid a

Results of a phase 3 study evaluating the efficacy and safety of Cimzia® (certolizumab pegol) in the treatment of Japanese patients with early rheumatoid arthritis (RA) are presented this week...

More...